Systematic investigation and comparison of US FDA-approved immunosuppressive drugs FK506, cyclosporine and rapamycin for neuromuscular regeneration following chronic nerve compression injury-Reference-Cited by-同舟云学术

Systematic investigation and comparison of US FDA-approved immunosuppressive drugs FK506, cyclosporine and rapamycin for neuromuscular regeneration following chronic nerve compression injury

Published:2021-11 Issue:11 Volume:16 Page:989-1003
ISSN:1746-0751
Container-title:Regenerative Medicine
language:en
Short-container-title:Regenerative Medicine

Author:

Degrugillier Lucas¹²,Prautsch Katharina M¹²,Schaefer Dirk J³,Guzman Raphael⁴,Kalbermatten Daniel F³⁵⁶,Schären Stefan⁷,Madduri Srinivas²³⁵⁶^ORCID

Affiliation:

1. Department of Pathology, University Hospital Basel, Hebelstrasse 20, Basel, 4021, Switzerland

2. Department of Biomedical Engineering, University of Basel, Gewerbestrasse 14, Allschwil, 4123, Switzerland

3. Department of Plastic, Reconstructive, Aesthetic & Hand Surgery, University Hospital Basel, University of Basel, Spitalstrasse 21, Basel, 4021, Switzerland

4. Department of Neurosurgery, University Hospital Basel, University of Basel, Spitalstrasse 21, Basel, 4021, Switzerland

5. Bioengineering & Neuroregeneration, Department of Surgery, Geneva University Hospitals & University of Geneva, Rue Michel-Servet 1, Geneva, 1211, Switzerland

6. Plastic, Reconstructive and Aesthetic Surgery, Department of Surgery, Geneva University Hospitals and University of Geneva, 1211 Geneva, 14, Switzerland

7. Department of Spinal Surgery, University Hospital Basel, 4021, Basel, Switzerland

Abstract

Aim: To compare therapeutic benefits of different immunophilin ligands for treating nerve injuries. Materials & methods: Cyclosporine, FK506 and rapamycin, were evaluated first in vitro on a serum-free culture of embryonic dorsal root ganglia followed by a new in vivo model of chronic nerve compression. Results: Outcomes of the in vitro study have shown a potent effect of cyclosporine and FK506, on dorsal root ganglia axonal outgrowth, comparable to the effect of nerve growth factor. Rapamycin exhibited only a moderate effect. The in vivo study revealed the beneficial effects of cyclosporine, FK506 and rapamycin for neuromuscular regeneration. Cyclosporine showed the better maintenance of the tissues and function. Conclusion: Cyclosporine, FK506 and rapamycin drugs showed potential for treating peripheral nerve chronic compression injuries.

Funder

Eurostars

Publisher

Future Medicine Ltd

Subject

Embryology,Biomedical Engineering

Link

https://www.futuremedicine.com/doi/pdf/10.2217/rme-2020-0130

Reference68 articles.

1. Nerve Physiology

2. Pathoanatomy and Pathophysiology of Nerve Root Compression

3. NERVE COMPRESSION SYNDROMES

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Biohacking Nerve Repair: Novel Biomaterials, Local Drug Delivery, Electrical Stimulation, and Allografts to Aid Surgical Repair;Bioengineering;2024-07-31

2. Parthanatos: Mechanisms, modulation, and therapeutic prospects in neurodegenerative disease and stroke;Biochemical Pharmacology;2024-03

3. Natural polysaccharides and their derivatives as potential medical materials and drug delivery systems for the treatment of peripheral nerve injuries;Carbohydrate Polymers;2023-09

4. Future Considerations in the Diagnosis and Treatment of Compressive Neuropathies of the Upper Extremity;Journal of Hand Surgery Global Online;2022-11